ArticleJournal of medical case reports2026
Paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features: a diagnostic challenge-a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParaneoplastic neurologic syndromes (PNS) are rare immune-mediated disorders that may precede the diagnosis of an underlying malignancy, including non-small cell lung cancer (NSCLC). Tumor heterogeneity in NSCLC, particularly in rare subtypes such as adenosquamous carcinoma, may result in variable histologic findings across different biopsy sites, posing significant diagnostic challenges. CASE PRESENTATION: We report a case of a 45-year-old Tanzanian male, a never-smoker, who presented with progressive neurologic symptoms, including ageusia, dystonia, paresthesia, and ataxia, without respiratory complaints. Brain Magnetic resonance imaging (MRI) demonstrated diffuse cerebral microhemorrhages, and extensive autoimmune and neuronal antibody testing was negative. He received intravenous methylprednisolone followed by an oral prednisolone taper with transient stabilization. Positron emission tomography-computed tomography (PET-CT) revealed an ill-defined FDG-avid right lower lobe lesion and vertebral metastases. Biopsy of a T10 vertebral lesion confirmed metastatic lung adenocarcinoma (TTF-1 positive), and the disease was staged as stage IV (cTxNxM1b). The patient was treated with carboplatin and pemetrexed, with partial neurologic improvement. During disease progression, repeat bronchoscopy biopsy revealed tumor cells with squamous features (p63 positive, patchy TTF-1 expression), raising the possibility of mixed histology (adenosquamous). However, histologic transformation cannot be completely excluded due to a lack of molecular analysis. His condition deteriorated rapidly, and he died from complications of advanced metastatic disease with progressive neurologic involvement.
conclusionThis case highlights the diagnostic challenges of antibody-negative paraneoplastic neurologic syndromes. The study underscores the important role of PET-CT in identifying occult malignancy and the role of repeat biopsy in progressive disease. Discordant histologic findings should be interpreted cautiously, as they may reflect tumor heterogeneity or possible adenosquamous carcinoma rather than true histologic evolution. Limited molecular testing, and sampling constraints remain important challenges, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.